Reham Waheed Mahmoud Hammad <br/><br/>
A pharmaceutical study on mosapride for intranasal administration /  
 دراسة صيدلية علي عقار الموزابريد لاستخدامة عن طريق الانف 
Reham Waheed Mahmoud Hammad ; Supervised Nevine Shawky Abdelmalak , Randa Latif Aziz , Rania Abdelbaset Sanad 
 - Cairo :   Reham Waheed Mahmoud Hammad ,   2019 
 - 229 P. :   charts ;   25cm 
<br/><br/>Thesis (M.Sc.) - Cairo University - Faculty of Pharmacy - Department of Industrial Pharmacy 
<br/><br/> Mosapride citrate (MOS) is a potent gastroprokinetic agent, used in the treatment of various gastrointestinal disorders caused by reduced gastrointestinal motility including gastroesophageal reflux disease (GERD). MOS would neither result in cardiac nor nervous adverse reactions due to selective stimulation of serotonin 5-HT4 receptors, without any considerable affinity for dopamine D2, 5-HT1, 5-HT2, or adrenergic receptors. Presently, available tablet dosage formulation of MOS is incapable to achieve the required clinical efficacy. Its short half-life (t1/2), intensive first-pass metabolism, poor solubility, and poor wettability lower its oral bioavailability to be 8-14%.This very low oral bioavailability restricts its use. So, the aim of this study was to improve the bioavailability MOS through intranasal administration 
<br/><br/>
<br/><br/><label>Subjects--Index Terms: </label>Mosapride citrate  Nasal  Xyloglucan